MANAGEMENT OF THE PATIENT WITH CHRONIC RENAL FAILURE IN THE EVIDENCE BASED ERA

REFERENCES:

• K/DOQI Clinical Practice Guidelines for Chronic Kidney Dis-ease: Evaluation, Classification and Stratification. Am J Kidney Dis 2002; 39: S1-S266, (suppl 1)
   Google Scholar
• NHANES III, Am J Kidney Dis 1998; 32: 992–9
   Web of Science ®Google Scholar
• US Renal Data system. USRDS 1998 Annual Data Report, Na-tional Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, 1998.
   Google Scholar
• Foley et al Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: 112–9.
   PubMed Web of Science ®Google Scholar
• Parfrey PS, Foley RN, Harnett JD et al. Outcome and risk fac-tors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11: 1277–85.
   PubMed Web of Science ®Google Scholar
• Mendelssohn, DC, Brandan JB, Brownscombe LM et al. Elevated levels of serum creatinine: Recommendations for management and referral. Can Med Assoc J 1999; 161:413–7.
   Web of Science ®Google Scholar
• Richtlijnen voor de behandeling van patiënten met chronische nierziekten. NBVN-WVVH guidelines. 2001. (www.nbvn.bei; www.wvvh.be)
   Google Scholar
• Hunsicker et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908–19.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Reasearch Group. The effect of intensive treatment of diabetes on the develop-ment and progression of long-term complications in insulin-de-pendent diabetes mellitus. N Eng J Med 1993; 329: 977–86.
   Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study Group: UK Pro-spective Diabetes Study 33: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lan-cet 1998; 352:837–53.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association, Clinical Practice Recommen-dations 2002. Diabetes Care 2002; 25 51.
   Google Scholar
• United Kingdom Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ 1998; 317:703–13.
   PubMed Web of Science ®Google Scholar
• Weidmann et al. Therapeutic efficacy of different antihyperten-sive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transplant 1995; 10 (suppl 9): 39–45
   PubMed Web of Science ®Google Scholar
• Mailloux LU, Levey AS. Hypertension in chronic renal disease. Am J Kidney Dis 1998; 32(S3): S120–S141.
   Web of Science ®Google Scholar
• Jafar et al AIPRD study, Angiotensin converting enzyme inhibi-tors and the progression of non-diabetic renal disease: a meta-analysis on patient level data. Ann Intern Med 2001, 135: 73–87.
   PubMed Web of Science ®Google Scholar
• K/DOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Am J Kidney Dis 2000; 35 S2.
   Google Scholar
• Fried LF, Orchard TJ, Kasiske BL. The effect of lipid reduction on renal disease progression: A meta-analysis. Kidney Int 2001; 59:260–9.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Williams M, Dworkin L et al. Poreserving renal func-tion in adults with hypertension and diabetes: A concensus ap-proach. Am J Kidney Dis 2000; 36: 646–61.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357:1601–8
   PubMed Web of Science ®Google Scholar
• Kean WF, Eknoyan G: Proteinuria, Albuminuria, Risk Assessment, Detection, Elimination (PARADE): A position paper of the Na-tional Kidney Foundation. Am J Kidney Dis 1999; 33: 1004–10.
   Web of Science ®Google Scholar
• The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Eng J Med 2000; 342:145–53.
   PubMed Web of Science ®Google Scholar
• Dahl& B, Devereux RB, Kjeldsen SE et al. Cardiovascular mor-bidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study: a randomised trial against atenolol. Lancet 2002; 359:995–1003.
   Google Scholar
• Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effect of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283–89.
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Harnett JD et al. The impact of anemia on cardiomyopathy; morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53–61.
   PubMed Web of Science ®Google Scholar
• Rigatto C, Jeffrey J, Foley RN et al. Risk factors for de novo congestive heart failure in renal transplant recipients. J Am Soc Nephrol 2000; 11: 705A.
   Google Scholar
• Foley RN, Parfrey PS, Progan J et al. Effect of haemoglobin levels in haemodialysis patients with asymptomatic cardiomy-opathy. Kidney Int 2000; 58: 1325–35.
   PubMed Web of Science ®Google Scholar
• Fink, JC, Blahut S, Reddy M, Light PD. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001; 37: 348–55
   PubMed Web of Science ®Google Scholar
• European Best Practice Guidelines for the Management of Anae-mia in Patients with Chronic Renal Failure. Nephrol Dial Trans-plant 1999; 14 S5:9–10.
   Google Scholar
• Salusky IB and Goodman WG. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 2002; 17: 336–9
   PubMed Web of Science ®Google Scholar